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The clinical problem
Atopic eczema affects many adults and up to 20% of 
children,1 with health costs comparable to diabetes2 
and asthma.3 One community survey of 1760 young 
children in the United Kingdom found that 84% had 
mild eczema, 14% moderate, and 2% severe eczema.4 
Topical corticosteroids are a mainstay of treatment 
for inflammatory episodes.5 Most long established 
topical corticosteroids such as betamethasone valer-
ate or hydrocortisone are applied at least twice daily, 
but three newer preparations (mometasone, fluti-
casone, and methylprednisolone) have been devel-
oped for once daily application. Here, I propose that 
established preparations need be applied only once 
daily.
The evidence for change
Ten randomised controlled trials compared once 
daily versus more frequent application of topical 
corticosteroids within the same potency group. The 
findings are summarised in a UK Health Technology 
Assessment report and guidance from the National 
Institute for Health and Clinical Excellence (NICE).6 7 
Another short term study has been published more 
recently.8 None of the studies found clear evidence 
that applying topical corticosteroids more than once 
a day produced better overall clinical outcomes in 
eczema, such as the number of people with a good 
response. Clear evidence of a faster response with 
more frequent use or a better response in subgroups 
such as children was lacking. No data were given on 
relapse rates.
The main adverse effect of topical corticosteroids 
is thinning of the skin.9 The studies included in the 
technology assessment were too short in duration 
(three to four weeks) to see if once daily application 
results in less skin thinning. However, as skin thin-
ning is related to the amount and duration of topical 
corticosteroid, its strength, and its site of application,10 
reducing the frequency of application could reduce 
local adverse effects.
It seems logical that applying topical corticoster-
oids once daily instead of twice daily would reduce 
costs by up to 50%. However, three newer potent 
topical corticosteroid preparations have been spe-
cifically manufactured and tested for once daily use 
(mometasone furoate, fluticasone propionate, and 
methylprednisolone aceponate7 11). Newer once daily 
preparations may still cost more than twice daily use 
of older preparations such as betamethasone valer-
ate. No trial has directly compared once daily beta-
methasone with once daily newer preparations. A 
blanket recommendation for a switch to once daily 
application of topical corticosteroids could paradoxi-
cally increase costs.6 This dilemma led to a mixed 
recommendation in the original NICE guidance to 
use topical corticosteroids once or twice daily and to 
use the cheapest alternative.7 Later papers have been 
more forthright in supporting once daily application 
of established corticosteroids.12 13
The barriers to change
The case for changing to once daily application of 
established corticosteroids is strong. It is based on 
lack of evidence of superior efficacy in 11 randomised 
controlled trials; cost savings of up to 50% to the state 
or patient if an established preparation such as beta-
methasone valerate 0.1% is considered; the conven-
ience to patients of applying preparations just once 
daily (important as a recent study suggested that mean 
adherence to twice daily topical corticosteroids was 
only 23%14); and the possibility that side effects such 
as skin thinning ca n be reduced. Conflicting written 
advice in package inserts can be overcome by coun-
selling patients beforehand. A change to once daily 
topical corticosteroids was suggested 10 years ago.15 
Perhaps the biggest barrier to change is habit.
How should we change our practice?
Patients using moderate, potent, or very potent topical 
corticosteroids more than once a day should switch to 
once daily use. However, the above evidence on short 
term use of mostly potent topical corticosteroids in 
people in secondary care may not be generalisable to 
those with very mild eczema using mild preparations, 
such as 1% hydrocortisone, for longer periods.
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KEy PoInTs
• Established topical corticosteroids such as 
betamethasone valerate have typically been used twice 
daily or more frequently for treating inflammatory episodes 
of eczema
• Reducing the frequency of application to once daily does 
not seem to result in loss of efficacy and could lead to fewer 
local side effects
• Using topical corticosteroids just once a day may be more 
convenient for patients and may save costs if established 
preparations are used
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